Latest Intelligence on Vaccines in Italy

Published within

« | 1 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Novartis: FDA refusal may relegate Menveo to second-to-market for toddlers

Novartis has announced the US approval of its licensed quadrivalent meningococcal vaccine, Menveo, in children aged two to 10; however, the FDA rejected an application for younger age groups. This represents a major setback for the firm, which is already struggling to gain share in the US meningococcal market due to the dominance of Sanofi Pasteur's competitor Menactra.

Published By Datamonitor
07 Feb 2011

« | 1 | » »|

No help is available.